Clinical trial results:
A Phase II Randomized Observer-Blind, Multicentre, Controlled Study of a Trivalent Group B Streptococcus Vaccine in Healthy Pregnant Women.

Due to a system error, the data reported in v1 is not correct and has been removed from public view.

Summary

EudraCT number	2010-020840-36
Trial protocol	BE Outside EU/EEA
Global end of trial date	17 October 2013

Results information

Result version number	v2 (current)
This version publication date	04 June 2016
First version publication date	25 April 2015
Version creation reason	• Correction of full data set re-QC of study is required because of the EudraCT system glitch and updates are required.

Trial information

Trial identification

Sponsor protocol code	V98_04

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01446289
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Novartis Vaccines and Diagnostics
Sponsor organisation address	Via Fiorentina, 1, Siena, Italy, 53100
Public contact	Posting Director, Novartis Vaccines and Diagnostics, RegistryContactVaccinesUS@novartis.com
Scientific contact	Posting Director, Novartis Vaccines and Diagnostics, RegistryContactVaccinesUS@novartis.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	14 May 2014
Is this the analysis of the primary completion data?	Yes
Primary completion date	08 April 2013
Global end of trial reached?	Yes
Global end of trial date	17 October 2013
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

To evaluate placental transfer of anti-Group B streptococcus (GBS) capsular polysaccharide (CPS) antibodies against vaccine serotypes among infants born to vaccine and placebo injected mothers.

Protection of trial subjects:

This clinical study was designed and was to be implemented and reported in accordance with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice (GCPs), with applicable local regulations (including European Directive 2001/20/EC, US Code of Federal Regulations Title 21, and Japanese Ministry of Health, Labor, and Welfare), and with the ethical principles laid down in the Declaration of Helsinki.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	09 September 2011
Long term follow-up planned	Yes
Long term follow-up rationale	Safety
Long term follow-up duration	6 Months
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Belgium: 60
Country: Number of subjects enrolled	Canada: 26
Worldwide total number of subjects	86
EEA total number of subjects	60

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0

Adults (18-64 years)	86
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Participants were recruited from 5 centres.

Pre-assignment

Screening details:

A total of 86 pregnant subjects were enrolled in the study. 86 infants were enrolled in this study, delivered by 86 maternal subjects. There were 86 singleton deliveries.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Arms

Are arms mutually exclusive?	Yes
Arm title	Mother GBS

Arm description:

Pregnant women who received one injection of GBS vaccine.

Arm type	Experimental
Investigational medicinal product name	Trivalent Group B Streptococcus Glycoconjugate Vaccine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder and solvent for solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

One 0.5 mL of vaccine (5/5/5 trivalent GBS diluted with WFI) is administered intramuscularly in the arm.

Arm title	Mothers Placebo

Arm description:

Pregnant women who received one injection of saline solution.

Arm type	Placebo
Investigational medicinal product name	Saline solution
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

One 0.5 mL of sterile saline is administered intramuscularly in the arm.

Number of subjects in period 1	Mother GBS	Mothers Placebo
Started	51	35
Completed	50	35
Not completed	1	0
Consent withdrawn by subject	1	-

Baseline characteristics

Reporting groups	
Reporting group title	Mother GBS
Reporting group description:	
Pregnant women who received one injection of GBS vaccine.	
Reporting group title	Mothers Placebo
Reporting group description:	
Pregnant women who received one injection of saline solution.	

Reporting group values	Mother GBS	Mothers Placebo	Total
Number of subjects	51	35	86
Age categorical			
Units: Subjects			
In utero			0
Preterm newborn infants (gestational age < 37 wks)			0
Newborns (0-27 days)			0
Infants and toddlers (28 days-23 months)			0
Children (2-11 years)			0
Adolescents (12-17 years)			0
Adults (18-64 years)			0
From 65-84 years			0
85 years and over			0
Age continuous			
Units: years			
arithmetic mean	29.7	30	
standard deviation	± 4.9	± 5.5	-
Gender categorical			
Units: Subjects			
Female	51	35	86
Male	0	0	0

End points

End points reporting groups

Reporting group title	Mother GBS
Reporting group description:	
Pregnant women who received one injection of GBS vaccine.	
Reporting group title	Mothers Placebo
Reporting group description:	
Pregnant women who received one injection of saline solution.	
Subject analysis set title	PPS- Primary Objective
Subject analysis set type	Per protocol
Subject analysis set description:	
•Provide at least one evaluable serum sample result at delivery (or within 72 hours after) for maternal subjects •Provide at least one evaluable serum sample result at birth (Day 1, or within 72 hours after) for infants	
Subject analysis set title	Infants-GBS
Subject analysis set type	Per protocol
Subject analysis set description:	
All infants born to maternal subjects who received GBS.	
Subject analysis set title	Infants-Placebo
Subject analysis set type	Per protocol
Subject analysis set description:	
All infants born to maternal subjects receiving placebo	
Subject analysis set title	Safety Set –Overall
Subject analysis set type	Safety analysis
Subject analysis set description:	
All maternal subjects in the Exposed Set who have either provided data on postvaccination unsolicited AEs or local or systemic AEs or other signs of reactogenicity.	
Subject analysis set title	PPS- Secondary Objective Maternal
Subject analysis set type	Per protocol
Subject analysis set description:	
Provide at least one evaluable serum sample result at Day 1 (prior to vaccination), Study Day 31, delivery, or Day 91 postpartum.	
Subject analysis set title	PPS- Secondary Objective Infants
Subject analysis set type	Per protocol
Subject analysis set description:	
Provide at least one evaluable serum sample result at birth (Day 1, or within 72 hours) and Day 91 of age.	

Primary: 1. Geometric Mean of the Ratios Between Infant Antibody Level (µg/mL) and Maternal Antibody Level (µg/mL) at Time of Delivery

End point title	1. Geometric Mean of the Ratios Between Infant Antibody Level (µg/mL) and Maternal Antibody Level (µg/mL) at Time of Delivery[1]
End point description:	
The Geometric mean transfer ratio of anti-GBS CPS antibodies against serotypes Ia, Ib and III at delivery is calculated as the geometric mean of the pairwise ratios between the antibody concentrations from infant at birth and to maternal serum concentration at delivery. The analysis was done on the Immunogenicity PPS.	
End point type	Primary
End point timeframe:	
Day of delivery/birth	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analysis is associated to this endpoint. Analyses were run descriptively.

End point values	Mother GBS	Mothers Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	45	30		
Units: Ratio				
geometric mean (confidence interval 95%)				
GBS Ia	0.81 (0.72 to 0.91)	0.97 (0.85 to 1.11)		
GBS Ib (N=40, 22)	0.77 (0.62 to 0.97)	1.44 (1.06 to 1.94)		
GBS III (N=40, 25,)	0.68 (0.59 to 0.78)	0.99 (0.83 to 1.18)		

Statistical analyses

No statistical analyses for this end point

Secondary: 2. GMCs (Enzyme-linked Immunosorbent Assay, ELISA) Antibodies Against Serotypes Ia, Ib and III in Maternal Subjects

End point title	2. GMCs (Enzyme-linked Immunosorbent Assay, ELISA) Antibodies Against Serotypes Ia, Ib and III in Maternal Subjects

End point description:

GMCs (ELISA) of anti-GBS CPS antibodies against serotypes Ia, Ib and III in maternal subjects at study day 1, study day 31 and at day 91 post-partum after one administration of GBS vaccine or placebo are reported.

The analysis was done on the Immunogenicity PPS.

End point type	Secondary

End point timeframe:

Day 1, day 31 and day 91 post-delivery

End point values	Mother GBS	Mothers Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	51	35		
Units: µg/mL				
geometric mean (confidence interval 95%)				
GBS Ia (day 1)	0.28 (0.19 to 0.41)	0.37 (0.24 to 0.58)		
GBS Ia (day 31; N=49, 32)	4.83 (2.89 to 8.06)	0.36 (0.19 to 0.65)		
GBS Ia (day 91 post-delivery; N = 44, 34)	5.89 (3.86 to 8.99)	0.46 (0.29 to 0.75)		

GBS Ib (day 1; N= 50, 34)	0.13 (0.084 to 0.19)	0.084 (0.051 to 0.14)		
GBS Ib (day 31; N=49, 31)	1.68 (0.97 to 2.92)	0.14 (0.069 to 0.27)		
GBS Ib (day 91 post-delivery; N= 44, 33)	3.46 (2.33 to 5.14)	0.17 (0.11 to 0.27)		
GBS III (day 1)	0.11 (0.07 to 0.16)	0.093 (0.056 to 0.15)		
GBS III (day 31; N= 49, 32)	1.46 (0.83 to 2.57)	0.12 (0.06 to 0.23)		
GBS III (day 91 post-delivery; N=44, 34)	2.69 (1.78 to 4.06)	0.11 (0.07 to 0.18)		

Statistical analyses

No statistical analyses for this end point

Secondary: 3. Geometric Mean Ratios (GMRs) of Antibody GMCs (ELISA) in Maternal Subjects

End point title	3. Geometric Mean Ratios (GMRs) of Antibody GMCs (ELISA) in Maternal Subjects

End point description:

GMRs of GMCs (ELISA) of anti-GBS CPS antibodies against serotypes Ia, Ib and III, in maternal subjects at study day 31, at delivery and at day 91 post-partum versus day 1 (baseline) after one administration of GBS vaccine or placebo are reported.

The analysis was done on the Immunogenicity PPS.

End point type	Secondary

End point timeframe:

Day 31, day of delivery, day 91 post-delivery.

End point values	Mother GBS	Mothers Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	51	35		
Units: Ratio				
geometric mean (confidence interval 95%)				
GBS Ia (Day 31/day 1; N=49, 32)	15 (9.12 to 25)	1.22 (0.66 to 2.25)		
GBS Ia (Delivery/day 1)	16 (11 to 25)	1.2 (0.72 to 2.01)		
GBS Ia (day 91 post-delivery/day 1; N= 44, 34)	19 (12 to 28)	1.51 (0.94 to 2.42)		
GBS Ib (Day 31/day 1; N=48, 30)	18 (9.94 to 32)	1.14 (0.56 to 2.35)		
GBS Ib (Delivery/day 1; N=50, 34)	23 (14 to 39)	1.13 (0.63 to 2.05)		
GBS Ib (day 91 post-delivery/day 1; N=44, 32)	33 (22 to 48)	1.53 (0.96 to 2.43)		
GBS III (Day 31/day 1; N=49, 32)	17 (9.17 to 30)	1.19 (0.59 to 2.42)		

GBS III (Delivery/day 1)	20 (12 to 33)	1.08 (0.6 to 1.96)		
GBS III (day 91 post-delivery/day 1; N=44, 34)	28 (18 to 43)	1.11 (0.69 to 1.8)		

Statistical analyses

No statistical analyses for this end point

Secondary: 4. GMC (ELISA) of Anti-GBS CPS Antibodies in Infants

End point title	4. GMC (ELISA) of Anti-GBS CPS Antibodies in Infants

End point description:

GMC (ELISA) of anti-GBS CPS antibodies against serotypes Ia, Ib and III in infants at birth and at 3 months of age are reported.

The analysis was done on the Immunogenicity PPS.

End point type	Secondary

End point timeframe:

Day of birth and day 91 after birth

End point values	Infants-GBS	Infants-Placebo		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	35	25		
Units: µg/mL				
geometric mean (confidence interval 95%)				
GBS Ia (day of birth)	5.14 (2.64 to 10)	0.33 (0.15 to 0.71)		
GBS Ia (day 91 after birth)	1.28 (0.76 to 2.16)	0.25 (0.13 to 0.46)		
GBS Ib (day of birth; N=31, 20)	2.93 (1.14 to 7.57)	0.1 (0.031 to 0.32)		
GBS Ib (day 91 after birth)	0.54 (0.25 to 19)	0.063 (0.025 to 0.16)		
GBS III (day of birth; N=30, 22)	1.93 (0.82 to 4.59)	0.065 (0.024 to 0.18)		
GBS III (day 91 after birth)	0.43 (0.21 to 0.86)	0.065 (0.029 to 0.15)		

Statistical analyses

No statistical analyses for this end point

Secondary: 5. GMRs of Anti-GBS CPS Antibody GMCs (ELISA) in Infants at 3 Months of Age Versus GMCs at Birth

End point title	5. GMRs of Anti-GBS CPS Antibody GMCs (ELISA) in Infants at 3 Months of Age Versus GMCs at Birth

End point description:

GMRs of anti-GBS CPS antibody GMCs (ELISA) against serotypes Ia, Ib and III in infants at 3 months of age (day 91 after birth) versus GMCs at birth are reported.

The analysis was done on the Immunogenicity PPS.

End point type	Secondary

End point timeframe:

Day 91 after birth

End point values	Infants-GBS	Infants-Placebo		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	35	25		
Units: Ratio				
geometric mean (confidence interval 95%)				
GBS Ia	0.25 (0.19 to 0.32)	0.76 (0.57 to 1.01)		
GBS Ib (N=31, 20)	0.22 (0.16 to 0.29)	0.54 (0.38 to 0.78)		
GBS III (N=30, 22)	0.25 (0.19 to 0.32)	0.85 (0.62 to 1.16)		

Statistical analyses

No statistical analyses for this end point

Secondary: 6. Percentages of Infant Subjects Showing Anti-diphtheria Antibody concentrations (ELISA) Over 0.1 IU/mL at 1 Month After the Last Routine Infant Immunization

End point title	6. Percentages of Infant Subjects Showing Anti-diphtheria Antibody concentrations (ELISA) Over 0.1 IU/mL at 1 Month After the Last Routine Infant Immunization

End point description:

Percentages of infant subjects showing anti-diphtheria antibody concentrations (ELISA) over 0.1 IU/mL in sera collected at 1 month after the last routine infant immunization (ie, either 5 months or 7 months after birth, depending on the vaccination schedule) are reported.

The analysis was done on the Immunogenicity PPS.

End point type	Secondary

End point timeframe:

1 month after the last routine infant immunization.

End point values	Infants-GBS	Infants-Placebo		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	40	27		
Units: Percentage				
number (confidence interval 95%)				
>=0.1 IU/mL	100 (91 to 100)	100 (87 to 100)		

Statistical analyses

No statistical analyses for this end point

Secondary: 7. Percentage of Maternal Subjects Reporting Solicited Local and Systemic Adverse Events (AEs)

End point title	7. Percentage of Maternal Subjects Reporting Solicited Local and Systemic Adverse Events (AEs)

End point description:

Percentage of maternal subjects reporting solicited local and systemic AEs and other indicators of reactogenicity from day 1 to 7 after vaccination are reported.

The analysis was done on the Safety Set, ie, all subjects in the enrolled population who received a study vaccination, provided post vaccination safety data, provided post-baseline safety data.

End point type	Secondary

End point timeframe:

From day 1 to 7 after vaccination.

End point values	Mother GBS	Mothers Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	50	34		
Units: Percentage of Subjects				
Induration (>=25 mm; N =49, 34)	6	0		
Swelling (>=25 mm; N =49, 34)	4	0		
Ecchymosis (>=25 mm; N =49, 34)	2	0		
Erythema (>=25 mm; N =49, 34)	6	0		
Pain (N =49, 34)	35	12		
Chills (N =49, 34)	4	3		
Fatigue (N =49, 34)	31	26		
Malaise (N =49, 34)	14	9		
Myalgia (N =49, 34)	27	3		
Headache (N =49, 34)	16	21		
Rash (N =49, 34)	2	3		
Arthralgia (N =49, 34)	4	9		
Nausea (N =49, 34)	6	9		
Fever, body temperature >38° C (N =49, 33)	0	0		
Any other	8	3		
Stayed home (N =50, 34)	2	0		

Use of analgesics/antipyretics (N =49, 34)	6	3		

Statistical analyses

No statistical analyses for this end point

Secondary: 8. Percentage of Maternal Subjects Reporting Unsolicited AEs and Serious Adverse Events (SAEs)

End point title	8. Percentage of Maternal Subjects Reporting Unsolicited AEs and Serious Adverse Events (SAEs)

End point description:

Percentage of maternal subjects reporting unsolicited AEs, SAEs, AEs requiring a non-routine physician's visit, AEs leading to withdrawal are reported.

The analysis was done on the Safety Set.

End point type	Secondary

End point timeframe:

All AEs were recorded until delivery, after delivery all AEs requiring a non-routine physician's visit and AEs leading to withdrawal from the study. SAEs were collected for the duration of the trial.

End point values	Mother GBS	Mothers Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	51	35		
Units: Percentage of subjects				
Any unsolicited AE	63	74		
Any SAE	14	23		
Medically-attended AEs	51	54		
AEs leading to withdrawal	0	0		

Statistical analyses

No statistical analyses for this end point

Secondary: 9. Percentages of Infants Reporting SAEs

End point title	9. Percentages of Infants Reporting SAEs

End point description:

Percentages of infants born from women who received either one injection of the study vaccine or placebo, reporting SAEs from birth until study termination are reported.

The analysis was done on the Safety Set.

End point type	Secondary

End point timeframe:

From birth until study termination

End point values	Infants-GBS	Infants-Placebo		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	51	35		
Units: Percentages of subjects				
Percentages of Infants Reporting SAEs	24	31		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Solicited (systematic) AEs were collected from day 1 to 7 after vaccination; unsolicited (non-systematic) AEs from day 1 until delivery, SAE from day 1 until study termination (day 151 for subjects enrolled in Belgium, day 211 for subjects in Canada).

Adverse event reporting additional description:

The analysis was done on the Safety Set and Aes>5% were based on meddra version 17.1

Assessment type	Non-systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	16.0

Reporting groups

Reporting group title	Mother GBS

Reporting group description:

Pregnant women who received one dose of GBS vaccine.

Reporting group title	Mother Placebo

Reporting group description:

Pregnant women who received one injection of saline solution.

Reporting group title	Infants GBS

Reporting group description:

Infants born to mothers who received one dose of GBS vaccine.

Reporting group title	Infants Placebo

Reporting group description:

Infants born to mothers who received one injection of saline solution.

Serious adverse events	Mother GBS	Mother Placebo	Infants GBS
Total subjects affected by serious adverse events			
subjects affected / exposed	7 / 51 (13.73%)	8 / 35 (22.86%)	12 / 51 (23.53%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
HAEMANGIOMA			
subjects affected / exposed	0 / 51 (0.00%)	0 / 35 (0.00%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Surgical and medical procedures			
CAESAREAN SECTION			

subjects affected / exposed	0 / 51 (0.00%)	1 / 35 (2.86%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
UTERINE CERVIX DILATION PROCEDURE			
subjects affected / exposed	1 / 51 (1.96%)	0 / 35 (0.00%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pregnancy, puerperium and perinatal conditions			
ARRESTED LABOUR			
subjects affected / exposed	1 / 51 (1.96%)	0 / 35 (0.00%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CEPHALO-PELVIC DISPROPORTION			
subjects affected / exposed	0 / 51 (0.00%)	1 / 35 (2.86%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
FOETAL DISTRESS SYNDROME			
subjects affected / exposed	1 / 51 (1.96%)	0 / 35 (0.00%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
FOETAL GROWTH RESTRICTION			
subjects affected / exposed	0 / 51 (0.00%)	1 / 35 (2.86%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
LOW BIRTH WEIGHT BABY			
subjects affected / exposed	0 / 51 (0.00%)	0 / 35 (0.00%)	1 / 51 (1.96%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PLACENTAL INSUFFICIENCY			
subjects affected / exposed	0 / 51 (0.00%)	1 / 35 (2.86%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PREMATURE DELIVERY			

subjects affected / exposed	0 / 51 (0.00%)	1 / 35 (2.86%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PRE-ECLAMPSIA			
subjects affected / exposed	0 / 51 (0.00%)	1 / 35 (2.86%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PREMATURE LABOUR			
subjects affected / exposed	0 / 51 (0.00%)	2 / 35 (5.71%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PREMATURE SEPARATION OF PLACENTA			
subjects affected / exposed	0 / 51 (0.00%)	1 / 35 (2.86%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SMALL FOR DATES BABY			
subjects affected / exposed	0 / 51 (0.00%)	0 / 35 (0.00%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
UMBILICAL CORD PROLAPSE			
subjects affected / exposed	0 / 51 (0.00%)	1 / 35 (2.86%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
UNSTABLE FOETAL LIE			
subjects affected / exposed	0 / 51 (0.00%)	1 / 35 (2.86%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
CRYING			
subjects affected / exposed	0 / 51 (0.00%)	0 / 35 (0.00%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PYREXIA			

subjects affected / exposed	1 / 51 (1.96%)	0 / 35 (0.00%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
OVARIAN CYST			
subjects affected / exposed	0 / 51 (0.00%)	0 / 35 (0.00%)	1 / 51 (1.96%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
VAGINAL HAEMORRHAGE			
subjects affected / exposed	0 / 51 (0.00%)	1 / 35 (2.86%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
APPARENT LIFE THREATENING EVENT			
subjects affected / exposed	0 / 51 (0.00%)	0 / 35 (0.00%)	1 / 51 (1.96%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ASPHYXIA			
subjects affected / exposed	0 / 51 (0.00%)	0 / 35 (0.00%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
NEONATAL ASPHYXIA			
subjects affected / exposed	0 / 51 (0.00%)	0 / 35 (0.00%)	1 / 51 (1.96%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
NEONATAL RESPIRATORY DISTRESS SYNDROME			
subjects affected / exposed	0 / 51 (0.00%)	0 / 35 (0.00%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
RESPIRATORY DISTRESS			

subjects affected / exposed	0 / 51 (0.00%)	0 / 35 (0.00%)	1 / 51 (1.96%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
TACHYPNOEA			
subjects affected / exposed	0 / 51 (0.00%)	0 / 35 (0.00%)	1 / 51 (1.96%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
TRANSIENT TACHYPNOEA OF THE NEW BORN			
subjects affected / exposed	0 / 51 (0.00%)	0 / 35 (0.00%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
ACUTE PSYCHOSIS			
subjects affected / exposed	1 / 51 (1.96%)	0 / 35 (0.00%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
POSTPARTUM DEPRESSION			
subjects affected / exposed	1 / 51 (1.96%)	0 / 35 (0.00%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
FOETAL MONITORING			
subjects affected / exposed	0 / 51 (0.00%)	1 / 35 (2.86%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
POST PROCEDURAL HAEMORRHAGE			
subjects affected / exposed	0 / 51 (0.00%)	1 / 35 (2.86%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital, familial and genetic disorders			
CATARACT CONGENITAL			

subjects affected / exposed	0 / 51 (0.00%)	0 / 35 (0.00%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
RENAL DYSPLASIA			
subjects affected / exposed	0 / 51 (0.00%)	0 / 35 (0.00%)	1 / 51 (1.96%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
RENAL HYPOPLASIA			
subjects affected / exposed	1 / 51 (1.96%)	0 / 35 (0.00%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
VENTRICULAR SEPTAL DEFECT			
subjects affected / exposed	0 / 51 (0.00%)	0 / 35 (0.00%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
TRISOMY 21			
subjects affected / exposed	0 / 51 (0.00%)	0 / 35 (0.00%)	1 / 51 (1.96%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
BRACHIAL PLEXOPATHY			
subjects affected / exposed	0 / 51 (0.00%)	0 / 35 (0.00%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
MYOCLONUS			
subjects affected / exposed	0 / 51 (0.00%)	0 / 35 (0.00%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PRESYNCOPE			
subjects affected / exposed	0 / 51 (0.00%)	0 / 35 (0.00%)	1 / 51 (1.96%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			

JAUNDICE ACHOLURIC			
subjects affected / exposed	0 / 51 (0.00%)	0 / 35 (0.00%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
JAUNDICE			
subjects affected / exposed	0 / 51 (0.00%)	0 / 35 (0.00%)	1 / 51 (1.96%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HYPERBILIRUBINAEMIA			
subjects affected / exposed	0 / 51 (0.00%)	0 / 35 (0.00%)	1 / 51 (1.96%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
RENAL HYPERTROPHY			
subjects affected / exposed	0 / 51 (0.00%)	0 / 35 (0.00%)	1 / 51 (1.96%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
FOOT DEFORMITY			
subjects affected / exposed	0 / 51 (0.00%)	0 / 35 (0.00%)	1 / 51 (1.96%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
APPENDICITIS			
subjects affected / exposed	0 / 51 (0.00%)	1 / 35 (2.86%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
GASTROENTERITIS			
subjects affected / exposed	1 / 51 (1.96%)	0 / 35 (0.00%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
RESPIRATORY SYNCYTIAL VIRUS BRONCHIOLITIS			

subjects affected / exposed	0 / 51 (0.00%)	0 / 35 (0.00%)	1 / 51 (1.96%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
RESPIRATORY SYNCYTIAL VIRUS INFECTION			
subjects affected / exposed	0 / 51 (0.00%)	0 / 35 (0.00%)	1 / 51 (1.96%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SEPSIS NEONATAL			
subjects affected / exposed	0 / 51 (0.00%)	0 / 35 (0.00%)	1 / 51 (1.96%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
URINARY TRACT INFECTION			
subjects affected / exposed	0 / 51 (0.00%)	0 / 35 (0.00%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
VIRAL INFECTION			
subjects affected / exposed	0 / 51 (0.00%)	0 / 35 (0.00%)	1 / 51 (1.96%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
DECREASED APPETITE			
subjects affected / exposed	0 / 51 (0.00%)	0 / 35 (0.00%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
FAILURE TO THRIVE			
subjects affected / exposed	0 / 51 (0.00%)	0 / 35 (0.00%)	1 / 51 (1.96%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
FEEDING DISORDER			
subjects affected / exposed	0 / 51 (0.00%)	0 / 35 (0.00%)	1 / 51 (1.96%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Infants Placebo		
Total subjects affected by serious adverse events			
subjects affected / exposed	11 / 35 (31.43%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
HAEMANGIOMA			
subjects affected / exposed	1 / 35 (2.86%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Surgical and medical procedures			
CAESAREAN SECTION			
subjects affected / exposed	0 / 35 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
UTERINE CERVIX DILATION PROCEDURE			
subjects affected / exposed	0 / 35 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pregnancy, puerperium and perinatal conditions			
ARRESTED LABOUR			
subjects affected / exposed	0 / 35 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
CEPHALO-PELVIC DISPROPORTION			
subjects affected / exposed	0 / 35 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
FOETAL DISTRESS SYNDROME			
subjects affected / exposed	0 / 35 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
FOETAL GROWTH RESTRICTION			

subjects affected / exposed	0 / 35 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
LOW BIRTH WEIGHT BABY				
subjects affected / exposed	0 / 35 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
PLACENTAL INSUFFICIENCY				
subjects affected / exposed	0 / 35 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
PREMATURE DELIVERY				
subjects affected / exposed	0 / 35 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
PRE-ECLAMPSIA				
subjects affected / exposed	0 / 35 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
PREMATURE LABOUR				
subjects affected / exposed	0 / 35 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
PREMATURE SEPARATION OF PLACENTA				
subjects affected / exposed	0 / 35 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
SMALL FOR DATES BABY				
subjects affected / exposed	1 / 35 (2.86%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
UMBILICAL CORD PROLAPSE				

subjects affected / exposed	0 / 35 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
UNSTABLE FOETAL LIE				
subjects affected / exposed	0 / 35 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
General disorders and administration site conditions				
CRYING				
subjects affected / exposed	1 / 35 (2.86%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
PYREXIA				
subjects affected / exposed	0 / 35 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Reproductive system and breast disorders				
OVARIAN CYST				
subjects affected / exposed	0 / 35 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
VAGINAL HAEMORRHAGE				
subjects affected / exposed	0 / 35 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Respiratory, thoracic and mediastinal disorders				
APPARENT LIFE THREATENING EVENT				
subjects affected / exposed	0 / 35 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
ASPHYXIA				

subjects affected / exposed	1 / 35 (2.86%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
NEONATAL ASPHYXIA				
subjects affected / exposed	0 / 35 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
NEONATAL RESPIRATORY DISTRESS SYNDROME				
subjects affected / exposed	1 / 35 (2.86%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
RESPIRATORY DISTRESS				
subjects affected / exposed	0 / 35 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
TACHYPNOEA				
subjects affected / exposed	0 / 35 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
TRANSIENT TACHYPNOEA OF THE NEW BORN				
subjects affected / exposed	1 / 35 (2.86%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Psychiatric disorders				
ACUTE PSYCHOSIS				
subjects affected / exposed	0 / 35 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
POSTPARTUM DEPRESSION				
subjects affected / exposed	0 / 35 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Investigations				

FOETAL MONITORING			
subjects affected / exposed	0 / 35 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
POST PROCEDURAL HAEMORRHAGE			
subjects affected / exposed	0 / 35 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Congenital, familial and genetic disorders			
CATARACT CONGENITAL			
subjects affected / exposed	1 / 35 (2.86%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
RENAL DYSPLASIA			
subjects affected / exposed	0 / 35 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
RENAL HYPOPLASIA			
subjects affected / exposed	0 / 35 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
VENTRICULAR SEPTAL DEFECT			
subjects affected / exposed	1 / 35 (2.86%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
TRISOMY 21			
subjects affected / exposed	0 / 35 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
BRACHIAL PLEXOPATHY			

subjects affected / exposed	1 / 35 (2.86%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
MYOCLONUS			
subjects affected / exposed	1 / 35 (2.86%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
PRESYNCOPE			
subjects affected / exposed	0 / 35 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
JAUNDICE ACHOLURIC			
subjects affected / exposed	1 / 35 (2.86%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hepatobiliary disorders			
JAUNDICE			
subjects affected / exposed	0 / 35 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
HYPERBILIRUBINAEMIA			
subjects affected / exposed	0 / 35 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
RENAL HYPERTROPHY			
subjects affected / exposed	0 / 35 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
FOOT DEFORMITY			

subjects affected / exposed	0 / 35 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
APPENDICITIS			
subjects affected / exposed	0 / 35 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
GASTROENTERITIS			
subjects affected / exposed	0 / 35 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
RESPIRATORY SYNCYTIAL VIRUS BRONCHIOLITIS			
subjects affected / exposed	0 / 35 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
RESPIRATORY SYNCYTIAL VIRUS INFECTION			
subjects affected / exposed	1 / 35 (2.86%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
SEPSIS NEONATAL			
subjects affected / exposed	0 / 35 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
URINARY TRACT INFECTION			
subjects affected / exposed	1 / 35 (2.86%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
VIRAL INFECTION			
subjects affected / exposed	1 / 35 (2.86%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			

DECREASED APPETITE			
subjects affected / exposed	1 / 35 (2.86%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
FAILURE TO THRIVE			
subjects affected / exposed	0 / 35 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
FEEDING DISORDER			
subjects affected / exposed	0 / 35 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Mother GBS	Mother Placebo	Infants GBS
Total subjects affected by non-serious adverse events			
subjects affected / exposed	33 / 51 (64.71%)	22 / 35 (62.86%)	0 / 51 (0.00%)
Nervous system disorders			
HEADACHE			
subjects affected / exposed	8 / 51 (15.69%)	10 / 35 (28.57%)	0 / 51 (0.00%)
occurrences (all)	11	13	0
General disorders and administration site conditions			
FATIGUE			
subjects affected / exposed	15 / 51 (29.41%)	9 / 35 (25.71%)	0 / 51 (0.00%)
occurrences (all)	17	12	0
INJECTION SITE ERYTHEMA			
subjects affected / exposed	7 / 51 (13.73%)	2 / 35 (5.71%)	0 / 51 (0.00%)
occurrences (all)	9	2	0
INJECTION SITE INDURATION			
subjects affected / exposed	6 / 51 (11.76%)	1 / 35 (2.86%)	0 / 51 (0.00%)
occurrences (all)	6	1	0
INJECTION SITE HAEMORRHAGE			
subjects affected / exposed	2 / 51 (3.92%)	3 / 35 (8.57%)	0 / 51 (0.00%)
occurrences (all)	2	4	0

INJECTION SITE PAIN			
subjects affected / exposed	17 / 51 (33.33%)	4 / 35 (11.43%)	0 / 51 (0.00%)
occurrences (all)	17	5	0
INJECTION SITE SWELLING			
subjects affected / exposed	4 / 51 (7.84%)	1 / 35 (2.86%)	0 / 51 (0.00%)
occurrences (all)	4	1	0
MALAISE			
subjects affected / exposed	7 / 51 (13.73%)	3 / 35 (8.57%)	0 / 51 (0.00%)
occurrences (all)	7	3	0
Gastrointestinal disorders			
HAEMORRHOIDS			
subjects affected / exposed	0 / 51 (0.00%)	3 / 35 (8.57%)	0 / 51 (0.00%)
occurrences (all)	0	3	0
NAUSEA			
subjects affected / exposed	4 / 51 (7.84%)	5 / 35 (14.29%)	0 / 51 (0.00%)
occurrences (all)	4	6	0
Reproductive system and breast disorders			
VAGINAL HAEMORRHAGE			
subjects affected / exposed	1 / 51 (1.96%)	2 / 35 (5.71%)	0 / 51 (0.00%)
occurrences (all)	1	2	0
Skin and subcutaneous tissue disorders			
RASH			
subjects affected / exposed	1 / 51 (1.96%)	2 / 35 (5.71%)	0 / 51 (0.00%)
occurrences (all)	1	2	0
Psychiatric disorders			
POSTPARTUM DEPRESSION			
subjects affected / exposed	1 / 51 (1.96%)	2 / 35 (5.71%)	0 / 51 (0.00%)
occurrences (all)	1	2	0
Musculoskeletal and connective tissue disorders			
MYALGIA			
subjects affected / exposed	13 / 51 (25.49%)	1 / 35 (2.86%)	0 / 51 (0.00%)
occurrences (all)	13	2	0
ARTHRALGIA			
subjects affected / exposed	2 / 51 (3.92%)	3 / 35 (8.57%)	0 / 51 (0.00%)
occurrences (all)	2	4	0
Infections and infestations			

CYSTITIS			
subjects affected / exposed	2 / 51 (3.92%)	2 / 35 (5.71%)	0 / 51 (0.00%)
occurrences (all)	2	2	0
BRONCHITIS			
subjects affected / exposed	3 / 51 (5.88%)	0 / 35 (0.00%)	0 / 51 (0.00%)
occurrences (all)	3	0	0
NASOPHARYNGITIS			
subjects affected / exposed	3 / 51 (5.88%)	3 / 35 (8.57%)	0 / 51 (0.00%)
occurrences (all)	4	3	0
URINARY TRACT INFECTION			
subjects affected / exposed	3 / 51 (5.88%)	1 / 35 (2.86%)	0 / 51 (0.00%)
occurrences (all)	3	1	0
VIRAL INFECTION			
subjects affected / exposed	0 / 51 (0.00%)	2 / 35 (5.71%)	0 / 51 (0.00%)
occurrences (all)	0	3	0

Non-serious adverse events	Infants Placebo		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	2 / 35 (5.71%)		
Nervous system disorders			
HEADACHE			
subjects affected / exposed	0 / 35 (0.00%)		
occurrences (all)	0		
General disorders and administration site conditions			
FATIGUE			
subjects affected / exposed	0 / 35 (0.00%)		
occurrences (all)	0		
INJECTION SITE ERYTHEMA			
subjects affected / exposed	0 / 35 (0.00%)		
occurrences (all)	0		
INJECTION SITE INDURATION			
subjects affected / exposed	0 / 35 (0.00%)		
occurrences (all)	0		
INJECTION SITE HAEMORRHAGE			
subjects affected / exposed	0 / 35 (0.00%)		
occurrences (all)	0		
INJECTION SITE PAIN			

subjects affected / exposed occurrences (all) INJECTION SITE SWELLING subjects affected / exposed occurrences (all) MALAISE subjects affected / exposed occurrences (all)	0 / 35 (0.00%) 0 0 / 35 (0.00%) 0 0 / 35 (0.00%) 0		
Gastrointestinal disorders HAEMORRHOIDS subjects affected / exposed occurrences (all) NAUSEA subjects affected / exposed occurrences (all)	 0 / 35 (0.00%) 0 0 / 35 (0.00%) 0		
Reproductive system and breast disorders VAGINAL HAEMORRHAGE subjects affected / exposed occurrences (all)	 0 / 35 (0.00%) 0		
Skin and subcutaneous tissue disorders RASH subjects affected / exposed occurrences (all)	 0 / 35 (0.00%) 0		
Psychiatric disorders POSTPARTUM DEPRESSION subjects affected / exposed occurrences (all)	 0 / 35 (0.00%) 0		
Musculoskeletal and connective tissue disorders MYALGIA subjects affected / exposed occurrences (all) ARTHRALGIA subjects affected / exposed occurrences (all)	 0 / 35 (0.00%) 0 0 / 35 (0.00%) 0		
Infections and infestations			

CYSTITIS			
subjects affected / exposed	0 / 35 (0.00%)		
occurrences (all)	0		
BRONCHITIS			
subjects affected / exposed	0 / 35 (0.00%)		
occurrences (all)	0		
NASOPHARYNGITIS			
subjects affected / exposed	2 / 35 (5.71%)		
occurrences (all)	3		
URINARY TRACT INFECTION			
subjects affected / exposed	0 / 35 (0.00%)		
occurrences (all)	0		
VIRAL INFECTION			
subjects affected / exposed	0 / 35 (0.00%)		
occurrences (all)	0		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
06 October 2011	Reference to infant blood draw by heel stick as the primary method was removed. The upper limit of the gestational age was revised from 24-34 weeks to 24-35 Weeks. At Visit 1 for the infant, the site staff should collect 10 mL of cord blood from the infant. If cord blood is not available, 0.5-1.0 mL of blood should be drawn from the infant. New pregnancies occurring within twelve (12) weeks of study vaccination will be captured on the Clinical Trial Pregnancy Form and reported to Novartis Clinical Safety & Epidemiology Department. Any pregnancies occurring past twelve (12) weeks of study vaccination are not considered as having exposure to the study vaccination, and are therefore not captured in this study. Additional description of assignment of the subject number by the blinded site staff and randomization code by the unblinded staff was added for clarity and to ensure blinding of trial.
05 September 2012	The description of an additional lot of the Novartis Group B streptococcus. Trivalent Glycoconjugate vaccine has been included in the protocol.
10 August 2013	Scheduled immunogenicity analysis has been removed due to the delay in running the immunogenicity assays at the laboratory Secondary endpoints have been modified The exploratory endpoint has been changed

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported